You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.
Ambry will provide RNA sequencing for Scipher's PrismRA blood test to predict response to TNF inhibitor therapies in rheumatoid arthritis patients.
An expanded agreement grants Qiagen a non-exclusive development license to Bio-Techne's exosome technology for the development of companion diagnostic products.
The collaboration seeks to standardize SARS-CoV-2 assays by defining concentrations of antibodies to specific viral proteins to confer neutralization.
The company and its collaborators previously published a study linking saliva concentrations of multiple microRNAs with concussion duration and symptoms in children.
The company's mobile app provides automated COVID-19 screening and directs potential patients to testing locations for confirmatory testing.
FIND has convened the Access to COVID-19 Tools Accelerator Diagnostic Pillar to supply 500 million tests to countries in the next year.
A new study aims to compare the detection performance of Helio Health's circulating tumor DNA assay with that of other screening modalities.
Cernostics offers an assay that analyzes whole-slide digital images with multiplexed fluorescence to help interpret Barrett's esophagus patient biopsies.
The test is based on 13 genes that form a gene signature in the blood of children with Kawasaki disease, and it enables KD to be distinguished from other diseases.